Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Familial Adenomatous Polyposis
NCT03649971Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, randomised, double-blind trial of guselkumab in familial adenomatous polyposis (FAP) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage Change from Baseline in Rectal/pouch Polyp Burden at 24 weeks. Started Nov 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT03649971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649971.